Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,071 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Memorial Sloan Kettering Cancer Center Clear all
Completed No phase listed Observational

Study of the Nevisense Device to Assess Atypical Skin Lesions

NCT04705168
View directory record Official record
Conditions
Nevus, Multiple Nevi, Large Acquired Nevi, Skin Lesion
Interventions
Nevisense electrical impedance spectroscopy
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

NCT03767257
View directory record Official record
Conditions
Multiple Myeloma, Diarrhea
Interventions
Colesevelam Pill
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 17, 2026, 9:09 PM EDT
Terminated Not applicable Interventional Results available

Pilot Trial of the Robotic Uterine Manipulator

NCT03517228
View directory record Official record
Conditions
Gynecologic Surgery
Interventions
BAUM device
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

NCT00526292
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
natural killer cell therapy, cyclophosphamide, fludarabine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 17, 2026, 9:09 PM EDT
Recruiting Phase 1 Interventional

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

NCT06616636
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Azacitidine, Rezatapopt
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00021034
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
chemotherapy, taurolidine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 17, 2026, 9:09 PM EDT
Active, not recruiting No phase listed Observational

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

NCT03127709
View directory record Official record
Conditions
Histiocytosis
Interventions
Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Terminated Phase 1Phase 2 Interventional

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

NCT04150965
View directory record Official record
Conditions
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Interventions
Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 17, 2026, 9:09 PM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors

NCT00003198
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ifosfamide, topotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer

NCT00615901
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 9:09 PM EDT
Completed No phase listed Observational Results available

Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)

NCT02571673
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 3 Interventional

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

NCT00003341
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
epoetin alfa, quality-of-life assessment
Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
18
States / cities
Berkeley, California • Los Angeles, California • Palm Springs, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 17, 2026, 9:09 PM EDT
Recruiting Not applicable Interventional

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

NCT05837767
View directory record Official record
Conditions
Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma, Lobular Breast Carcinoma Stage IV, Non Small Cell Lung Cancer, NSCLC, Gastrointestinal Cancer, Gastrointestinal Squamous Cell Cancer, Gastrointestinal Adenocarcinoma, Pancreatic Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Metastatic Solid Tumor
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00616941
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 2 Interventional

Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma

NCT00005631
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, etoposide, ifosfamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 17, 2026, 9:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

NCT05540392
View directory record Official record
Conditions
Survivorship, Prostate Cancer
Interventions
Acupuncture, Waitlist Control, Questionnaires
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Recruiting Phase 2 Interventional

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT05736419
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Interventions
Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Prospective Registry of Multiplex Testing (PROMPT)

NCT02665195
View directory record Official record
Conditions
Genetic Testing
Interventions
saliva specimen, questionnaire
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
10
States / cities
Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors

NCT00043095
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 2 Interventional

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00045422
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, imatinib mesylate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00006041
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
MUC1-KLH conjugate vaccine, MUC1-KLH vaccine/QS21, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 17, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

NCT02535286
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Umbralisib, ublituximab, TG-1501
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 17, 2026, 9:09 PM EDT